Skip to Main Content

Cassava Sciences had long claimed that its experimental treatment for Alzheimer’s disease was capable of improving the cognition of patients — a benefit no other Alzheimer’s drug has ever shown.

But mid-stage study results updated on Tuesday now show the cognitive status of patients worsening to the point where Cassava’s drug, called simufilam, doesn’t look any more effective than a placebo.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment